Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,517 across all filing types
Latest filing 2024-12-20 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 87% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group about obtaining clinical trial approval for a new product. It does not contain financial results, board changes, dividends, or other specific filing content. It is a general regulatory announcement filed on the Hong Kong Exchange. There is no specialized category for clinical trial approvals, so it defaults to the fallback “Regulatory Filings” category.
2024-12-20 English
CONNECTED TRANSACTIONS AND CONTINUING CONNECTED TRANSACTION
Regulatory Filings Classification · 91% confidence The document is an announcement by CSPC Pharmaceutical Group Limited filed on the Hong Kong Stock Exchange under Chapter 14A of the Listing Rules concerning connected transactions and continuing connected transactions (renewed lease agreements and energy supply services agreement). It is not an earnings release, management change, dividend notice, M&A, legal proceeding, or other specialized category. It is a regulatory announcement/disclosure required under listing rules and thus fits the fallback category “Regulatory Filings” (RNS).
2024-12-19 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 87% confidence The document is a Next Day Disclosure Return (HKEX form FF305) detailing changes in issued shares and treasury shares, specifically share repurchases for cancellation (on-market buybacks) and repurchase report under Main Board/GEM rules. This is a mandatory regulatory disclosure of the company’s own share transactions (buybacks), fitting the definition of a Transaction in Own Shares.
2024-12-19 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Exchange form (FF305) disclosing changes in issued shares, repurchases for cancellation, and on-market share buybacks. It details the number of shares repurchased, prices paid, and closing balances. This is clearly a report of the company’s own share transactions (repurchase of its own shares), matching the definition of Transaction in Own Shares (POS).
2024-12-18 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 94% confidence The document is a Next Day Disclosure Return (Form FF305) under HKEX rules detailing changes in issued and treasury shares, specifically the company’s share repurchases on the Exchange (Sections I and II). It is not a fundraising or dividend notice, but a report of on-market repurchases of its own shares. This matches the definition of a Transaction in Own Shares (share buyback) rather than a new issue or general capital update.
2024-12-17 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 92% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Exchange listing rules, detailing changes in issued shares and specifically reporting share repurchases (Part B) and the mandatory Repurchase Report (Section II). It is a report of the company buying back its own shares. This corresponds to our category “Transaction in Own Shares” (Code: POS).
2024-12-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.